Current AI programs miss the mark in my opinion. Some promising but a lot that needs to be improved!

Very vulnerable piece and really paints a great picture of today’s academic oncologist and trajectory of maybe others in a world where academics increasingly becomes more administrative and research focused.

Does this change your practice in terms of doing more neoadjuvant chemotherapy to downstage those more locally advanced HR+ tumors upfront and in premenopausal females?

I find this study very thought provoking and see the implications of financial toxicity with CDK4/6s, but are the patients we do this in ideally lower volume disease and bone only disease? Doing single agent AI for those with higher volume or visceral disease seems a bit risky to me practically.